COMBINATION COMPOSITION, COMPRISING AS ACTIVE INGREDIENTS L-CARNITlNE OR PROPIONYL L-CARNITlNE, FOR THE PREVENTION OR TREATMENT OF CHRONIC VENOUS INSUFFICIENCY

Abstract

It is described a combination composition comprising as active ingredients L-carnitine or propionyl L-carnitine, troxerutine, diosmine and hesperidine, useful for the prevention and/or treatment of chronic venous diseases.

1 . Composition comprising as active ingredients L-carnitine or a derivative or a salt thereof, troxerutine, diosmine and hesperidine, and optionally one or more pharmaceutically acceptable excipients. 
     
     
         2 . Composition of  claim 1 , wherein the derivative of L-carnitine is propionyl L-carnitine. 
     
     
         3 . Composition of  claim 1  comprising:
 L-carnitine or propionyl L-carnitine, in a dose of from 10 to 3000 mg; 
 troxerutine, in a dose of from 900 mg to 50 mg; 
 diosmine, in a dose of from 900 mg to 50 mg; and 
 hesperidine in a dose of from 10 mg to 500 mg. 
 
     
     
         4 - 5 . (canceled) 
     
     
         6 . Composition of  claim 1 , further comprising co-enzymes, mineral substances, antioxidants, vitamins and anticlotting agents. 
     
     
         7 . (canceled) 
     
     
         8 . Method of preventing or treating diseases of the vein comprising administering to a human subject in need thereof a composition comprising as active ingredients L-carnitine or a derivative or a salt thereof, troxerutine, diosmine and hesperidine. 
     
     
         9 . Method according to  claim 8  in which the derivative of L-carnitine is propionyl L-carnitine. 
     
     
         10 . Method according to  claim 8 , wherein the disease of the veins is selected from the group consisting of: chronic venous insufficiency, chronic venous disease and complication thereof. 
     
     
         11 . Method according to  claim 10 , wherein said complication is selected from the group consisting of: swelling and inflammation of veins in the rectum, anus and vulva; venous hypertension; increased permeability; oedema; capillary damage; skin changes; venous leg ulcers; swelling ankles; heavy legs; varicose veins; swelling leg; ulcers; vein thrombosis; phlebitis; thrombo-phlebitis; pulmonary embolus and hemorrhoids. 
     
     
         12 . Method according to  claim 8 , wherein the salt of L-camitine or propionyl L-carnitine is selected from the group consisting of: chloride, bromide, orotate, aspartate, acid aspartate, acid citrate, magnesium citrate, phosphate, acid phosphate, fumarate and acid fumarate, magnesium fumarate, lactate, maleate and acid maleate, oxalate, acid oxalate, pamoate, acid pamoate, sulphate, acid sulphate, glucose phosphate, tartrate and acid tartrate, glycerophosphate, ethanesulphonate, mucate, magnesium tartrate, 2-amino-ethanesulphonate, magnesium 2-amino-ethanesulphonate, methanesulphonate, choline tartrate, trichloroacetate, and trifluoroacetate. 
     
     
         13 . Method according to  claim 8 , for oral, parenteral, intravenous, topical and/or transdermal administration. 
     
     
         14 . Method according to  claim 8 , for oral administration. 
     
     
         15 . Composition of  claim 1  comprising L-carnitine or propionyl L-carnitine in a dose of from 50 mg to 400 mg. 
     
     
         16 . Composition of  claim 1  comprising L-carnitine or propionyl L-carnitine in a dose of 136 mg. 
     
     
         17 . Composition of  claim 1  comprising troxerutine in a dose from 200 mg to 400 mg. 
     
     
         18 . Composition of  claim 1  comprising troxerutine in a dose of 300 mg. 
     
     
         19 . Composition of  claim 1  comprising diosmine in a dose from 200 mg to 400 mg. 
     
     
         20 . Composition of  claim 1  comprising diosmine in a dose of 300 mg. 
     
     
         21 . Composition of  claim 1  comprising hesperidine in a dose of from 50 mg to 200 mg. 
     
     
         22 . Composition of  claim 1  comprising hesperidine in a dose of 100 mg.